Press Releases

Investors & Media

 
Press Releases
  Date Title and Summary View
Oct 13, 2016
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the acceptance of four abstracts for presentation at the 55th Annual Meeting of the American College of Neu...
Sep 26, 2016
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
Sep 2, 2016
WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the 23rd Annual NewsMakers in the Biotech Industry conference in New Yo...
Aug 4, 2016
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major depressive disorder WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) --  Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical com...
Jul 28, 2016
Management to host conference call WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the seco...
Jun 27, 2016
WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced that the Company has been added to the Russell 3000® Index and the Russell 2000® Index.  Trading in these newly reconstituted indexes will begin when the equity markets open on June 27,...
Jun 14, 2016
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities Life Sciences Conference in New York on Tuesday, June 2...
Jun 14, 2016
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $9.50 per share. Proceeds to Minerva from the offering, before deducting underwr...
Jun 13, 2016
WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to...
Jun 1, 2016
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 Healthcare Conference on June 8, 2016 at 11:00 a.m. E...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase